Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The…
GUANGZHOU, China, May 27, 2026 /PRNewswire/ -- Guided by the ONE GAC 2.0 global strategy, GAC has entered a new…
Data from randomized, double-blind study in 226 adults to be presented as an oral abstract May 26, 2026 07:00 ET…
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary…
BENGALURU, India, May 19, 2026 /PRNewswire/ -- GameChange Solar, a leading global supplier of solar tracker and fixed-tilt racking technology,…
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect…
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed…
May 15, 2026 20:19 ET | Source: Regeneron Pharmaceuticals, Inc. The trial did not reach statistical significance for the primary…
100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET |…
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events…